Department of Dermatology, Aichi Medical University, Nagakute, Aichi, Japan.
J Cutan Med Surg. 2023 Sep-Oct;27(5):481-486. doi: 10.1177/12034754231191062. Epub 2023 Aug 3.
The most important problem with local injections of botulinum toxin type A (BTX-A) in palmar hyperhidrosis is pain during the injections.
We evaluated therapeutic effectiveness and pain of local injections of BTX-A using needle-free direct administration system.
We performed BTX-A local injection therapy using a conventional injection needle in the left hand and a needle-free direct administration system in the right hand.
A reduction in the quantity of perspiration was observed 4 weeks after administration of both Needle and Needle-free BTX-A, and reduction was maintained throughout 28 weeks observation period. Both hyperhidrosis Disease Severity Scale scores and Dermatology Life Quality Index for hands treated with Needle BTX-A and hands treated with Needle-free BTX-A had decreased significantly by 4 weeks after treatment. Pain visual analog scale scores and the degree of pain were significantly lower in hands treated with Needle-free BTX-A than in hands treated with Needle BTX-A.
When the trigger of the pressurized needle-free injector device is activated, the gas powered driving pressure propels BTX-A through an orifice (0.13 mm) about four times narrower than a 30 G needle at very high speed. As most pain occurs during the needle prick itself, the advantage of a small orifice coupled with high-speed penetration of BTX-A through the pressurized device results in reduced pain during administration. The needle-free direct administration system administers the injectate under the skin without a visible needle.
手部多汗症局部注射肉毒毒素 A(BTX-A)最重要的问题是注射时疼痛。
我们评估了使用无针直接给药系统局部注射 BTX-A 的治疗效果和疼痛。
我们使用传统注射针在左手进行 BTX-A 局部注射治疗,在右手使用无针直接给药系统。
两种针(Needle)和无针(Needle-free)BTX-A 给药后 4 周均观察到出汗量减少,整个 28 周观察期内均维持减少。经 Needle BTX-A 治疗的手和经 Needle-free BTX-A 治疗的手的多汗症严重程度量表评分和手部皮肤病生活质量指数均在治疗后 4 周显著降低。经无针 BTX-A 治疗的手的疼痛视觉模拟评分和疼痛程度明显低于经针 BTX-A 治疗的手。
当加压无针注射器装置的触发装置被激活时,气体驱动压力会以非常高的速度将 BTX-A 通过一个比 30G 针头窄约四倍的小孔(0.13mm)推进。由于大多数疼痛发生在针刺本身,因此小孔和高压 BTX-A 快速穿透给药装置的结合导致给药时疼痛减轻。无针直接给药系统在皮肤下给药,看不到针。